JP2021042159A5 - - Google Patents

Download PDF

Info

Publication number
JP2021042159A5
JP2021042159A5 JP2019165017A JP2019165017A JP2021042159A5 JP 2021042159 A5 JP2021042159 A5 JP 2021042159A5 JP 2019165017 A JP2019165017 A JP 2019165017A JP 2019165017 A JP2019165017 A JP 2019165017A JP 2021042159 A5 JP2021042159 A5 JP 2021042159A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
active compound
pharmaceutically active
derivative
mol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019165017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021042159A (ja
JP7390830B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2019165017A priority Critical patent/JP7390830B2/ja
Priority claimed from JP2019165017A external-priority patent/JP7390830B2/ja
Publication of JP2021042159A publication Critical patent/JP2021042159A/ja
Publication of JP2021042159A5 publication Critical patent/JP2021042159A5/ja
Priority to JP2023197093A priority patent/JP2024009146A/ja
Application granted granted Critical
Publication of JP7390830B2 publication Critical patent/JP7390830B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019165017A 2019-09-11 2019-09-11 医薬活性化合物の苦味抑制剤及び苦味抑制方法 Active JP7390830B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019165017A JP7390830B2 (ja) 2019-09-11 2019-09-11 医薬活性化合物の苦味抑制剤及び苦味抑制方法
JP2023197093A JP2024009146A (ja) 2019-09-11 2023-11-21 医薬活性化合物の苦味抑制剤及び苦味抑制方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019165017A JP7390830B2 (ja) 2019-09-11 2019-09-11 医薬活性化合物の苦味抑制剤及び苦味抑制方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023197093A Division JP2024009146A (ja) 2019-09-11 2023-11-21 医薬活性化合物の苦味抑制剤及び苦味抑制方法

Publications (3)

Publication Number Publication Date
JP2021042159A JP2021042159A (ja) 2021-03-18
JP2021042159A5 true JP2021042159A5 (enrdf_load_stackoverflow) 2022-09-15
JP7390830B2 JP7390830B2 (ja) 2023-12-04

Family

ID=74863742

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019165017A Active JP7390830B2 (ja) 2019-09-11 2019-09-11 医薬活性化合物の苦味抑制剤及び苦味抑制方法
JP2023197093A Pending JP2024009146A (ja) 2019-09-11 2023-11-21 医薬活性化合物の苦味抑制剤及び苦味抑制方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023197093A Pending JP2024009146A (ja) 2019-09-11 2023-11-21 医薬活性化合物の苦味抑制剤及び苦味抑制方法

Country Status (1)

Country Link
JP (2) JP7390830B2 (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230173533A (ko) * 2022-06-17 2023-12-27 주식회사 코아팜바이오 신규한 구강용해산 조성물
CN119564602A (zh) * 2025-02-08 2025-03-07 江苏长泰药业股份有限公司 一种盐酸托莫西汀口服溶液的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015223A1 (en) 1998-09-15 2000-03-23 Eli Lilly And Company Treatment of persistent pain
AU5535900A (en) * 1999-07-01 2001-01-22 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
JP2005501070A (ja) * 2001-08-08 2005-01-13 イーライ・リリー・アンド・カンパニー 神経障害を処置するための組み合わせ療法
EP1904039A2 (en) 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
WO2009084017A2 (en) * 2007-10-10 2009-07-09 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2010150219A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof
CN102579403B (zh) 2011-12-26 2013-08-21 天津市嵩锐医药科技有限公司 盐酸度洛西汀药物组合物
US9855228B1 (en) * 2016-12-14 2018-01-02 Taho Pharmaceuticals Ltd. Oral solution comprising atomoxetine hydrochloride and methods thereof
US11266658B2 (en) 2017-03-03 2022-03-08 Ctc Bio, Inc. Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration

Similar Documents

Publication Publication Date Title
JP2008513467A5 (enrdf_load_stackoverflow)
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
JP2017105763A5 (enrdf_load_stackoverflow)
EP4293009A3 (en) Fenfluramine compositions and methods of preparing the same
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
TW200716202A (en) Pediatric formulation of topiramate
NZ597109A (en) Tablet composition having favorable dissolution property useful as an anticoagulant
JP2010513478A5 (enrdf_load_stackoverflow)
JP2014129360A5 (enrdf_load_stackoverflow)
NO20062619L (no) Doseringssystem med kontrollert frigivning for nasale anvendelser
JP2008044957A (ja) 抗真菌マニキュア組成物
HK1222297A1 (zh) 一種包含ampk激活劑及血清素活性製劑之醫藥組合物及其用途
RS51585B (en) AEROSOLIC INHALATION FORMULATION CONTAINING ANTICHOLINERGIC
JP2021042159A5 (enrdf_load_stackoverflow)
JP2013538853A5 (enrdf_load_stackoverflow)
CN111032644A (zh) 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
EA201990501A1 (ru) Фармацевтическая композиция
HRP20192010T1 (hr) Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
CN112789277A (zh) 胍类衍生物及其用途
JP2019151627A5 (enrdf_load_stackoverflow)
RS54420B1 (en) FORMULATION CONTAINING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE INGREDIENT
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
IL273430B2 (en) Crystalline form ii of 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}acetic acid Pharmaceutical preparation, pgi2 receptor agonist and therapeutic agent containing the crystal.